Core Insights - Cartesian Therapeutics has enrolled the first participant in its Phase 3 AURORA trial for Descartes-08, a cell therapy for myasthenia gravis (MG) [1][3] - Descartes-08 is an autologous engineered CAR-T therapy targeting B-cell maturation antigen (BCMA), designed for outpatient administration without preconditioning chemotherapy [2][5] - The Phase 3 trial aims to compare Descartes-08 to a placebo in approximately 100 participants, focusing on improvements in MG Activities of Daily Living (MG-ADL) scores [3][4] Company Overview - Cartesian Therapeutics is a clinical-stage biotechnology company focused on cell therapy for autoimmune diseases, with Descartes-08 as its lead asset in Phase 3 development for generalized MG [5] - The company is also developing Descartes-15, a next-generation CAR-T therapy currently in Phase 1 trials for multiple myeloma [5] Clinical Trial Details - The Phase 3 AURORA trial will randomize participants 1:1 to receive either Descartes-08 or placebo, with the primary endpoint being a three-point improvement in MG-ADL scores at Month 4 [3][4] - Previous Phase 2b trial results showed a significant average reduction of 4.8 points in MG-ADL scores at Month 12, with even greater reductions in patients without prior biologic therapy [4]